(window.webpackJsonp=window.webpackJsonp||[]).push([[4],{610:function(t,n,e){},611:function(t,n,e){},612:function(t,n,e){"use strict";e(610)},613:function(t,n,e){"use strict";e(611)},614:function(t,n,e){"use strict";e.r(n);e(613);var c=e(69),component=Object(c.a)({},(function(){var t=this.$createElement;this._self._c;return this._m(0)}),[function(){var t=this.$createElement,n=this._self._c||t;return n("div",{staticClass:"wrap-banner"},[n("div",{staticClass:"banner"},[n("p",[this._v("帮助你了解最新的医药 新闻，保健小知识")])])])}],!1,null,"20808ed0",null);n.default=component.exports},620:function(t,n,e){"use strict";e.r(n);e(36);var c=e(6).a.extend({mounted:function(){var t=this;this.$nextTick((function(){t.$nuxt.$loading.start(),setTimeout((function(){return t.$nuxt.$loading.finish()}),500)}))}}),C=(e(612),e(69)),component=Object(C.a)(c,(function(){var t=this,n=t.$createElement,e=t._self._c||n;return e("div",{staticClass:"container"},[e("div",[e("Banner"),t._v(" "),e("div",{staticClass:"gutter-example"},[e("div",{staticClass:"title"},[t._v("医药新闻")]),t._v(" "),e("a-row",{attrs:{gutter:16}},[e("a-col",{staticClass:"gutter-row",attrs:{span:8}},[e("div",{staticClass:"gutter-box"},[e("div",{staticClass:"row-title"},[t._v("\n              科济生物CT053全人抗BCMA CAR T细胞注射液纳入突破性治疗品种\n            ")]),t._v(" "),e("p",{staticClass:"desc"},[t._v("\n              12月8日，科济生物宣布，其CT053全人抗BCMA自体CAR\n              T细胞注射液通过CDE公示期，纳入突破性治疗药物品种，拟定适应症为复发难治性多发性骨髓瘤(R/R\n              MM)。宣布，其CT053全人抗BCMA自体CAR\n              T细胞注射液通过CDE公示期，纳入突破性治疗\n            ")]),t._v(" "),e("p",{staticClass:"time"},[t._v("2020-12-09 15:12")])])]),t._v(" "),e("a-col",{staticClass:"gutter-row",attrs:{span:8}},[e("div",{staticClass:"gutter-box"},[e("div",{staticClass:"row-title"},[t._v("\n              科济生物CT053全人抗BCMA CAR T细胞注射液纳入突破性治疗品种\n            ")]),t._v(" "),e("p",{staticClass:"desc"},[t._v("\n              12月8日，科济生物宣布，其CT053全人抗BCMA自体CAR\n              T细胞注射液通过CDE公示期，纳入突破性治疗药物品种，拟定适应症为复发难治性多发性骨髓瘤(R/R\n              MM)。宣布，其CT053全人抗BCMA自体CAR\n              T细胞注射液通过CDE公示期，纳入突破性治疗\n            ")]),t._v(" "),e("p",{staticClass:"time"},[t._v("2020-12-09 15:12")])])]),t._v(" "),e("a-col",{staticClass:"gutter-row",attrs:{span:8}},[e("div",{staticClass:"gutter-box"},[e("div",{staticClass:"row-title"},[t._v("\n              科济生物CT053全人抗BCMA CAR T细胞注射液纳入突破性治疗品种\n            ")]),t._v(" "),e("p",{staticClass:"desc"},[t._v("\n              12月8日，科济生物宣布，其CT053全人抗BCMA自体CAR\n              T细胞注射液通过CDE公示期，纳入突破性治疗药物品种，拟定适应症为复发难治性多发性骨髓瘤(R/R\n              MM)。宣布，其CT053全人抗BCMA自体CAR\n              T细胞注射液通过CDE公示期，纳入突破性治疗\n            ")]),t._v(" "),e("p",{staticClass:"time"},[t._v("2020-12-09 15:12")])])])],1)],1)],1)])}),[],!1,null,"305805e2",null);n.default=component.exports;installComponents(component,{Banner:e(614).default})}}]);